english.prescrire.org > Spotlight > Archives : 2025 > Dupilumab in severe asthma in children: helpful and without risk of infections or cancer?

Spotlight: Archives

Every month, the subjects in Prescrire’s Spotlight.

Dupilumab in severe asthma in children: helpful and without risk of infections or cancer?

 Queries and Comments   Following the publication of Prescrire's analysis of evaluation data for dupilumab (Dupixent°) in severe asthma in children aged 6 years or older (Prescrire Int October 2023), members of Crisalis, an international clinical research network studying severe asthma, wrote to express their differing conclusions on dupilumab's benefits and harms in this situation.
Full article available for download by subscribers (3 pages)

©Prescrire 1 January 2025

Source: "Dupilumab in severe asthma in children: helpful and without risk of infections or cancer?" Prescrire Int 2025; 34 (266): 18-20. Subscribers only.

Enjoy full access to Prescrire International, and support independent information

 
Share
Share on Facebook Share on Twitter
 
 
See also:

"Dupilumab (Dupixent°)
in severe asthma
from 6 years of age"
Prescrire Int 2023;